Attenuation of steatohepatitis, fibrosis, and carcinogenesis in mice fed a methionine-choline deficient diet by CCAAT/enhancer-binding protein homologous protein deficiency

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 5, 2014, Pages 1109-1118

  Toriguchi, Kan ^a   Hatano, Etsuro ^a   Tanabe, Kazutaka ^a   Takemoto, Kenji ^a   Nakamura, Kojiro ^a   Koyama, Yukinori ^a   Seo, Satoru ^a   Taura, Kojiro ^a   Uemoto, Shinji ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

CCAAT enhancer binding protein homologous protein; Hepatocellular carcinoma; Nonalcoholic steatohepatitis

Indexed keywords

BILIRUBIN; CCAAT ENHANCER BINDING PROTEIN; CHOLINE; CYTOKINE; DIETHYLNITROSAMINE; FAT; KI 67 ANTIGEN; LIVER ENZYME; MESSENGER RNA; METHIONINE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER GROWTH; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LIPID STORAGE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER INJURY; LIVER PROTECTION; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUTRITION; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; WILD TYPE; ANIMAL; C57BL MOUSE; CARCINOMA, HEPATOCELLULAR; DEFICIENCY; FATTY LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; VERY ELDERLY; VITAMIN DEFICIENCY;

AGED; AGED, 80 AND OVER; ANIMALS; CARCINOMA, HEPATOCELLULAR; CCAAT-ENHANCER-BINDING PROTEINS; CHOLINE DEFICIENCY; FATTY LIVER; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; METHIONINE; MICE, INBRED C57BL; MIDDLE AGED; MOLECULAR TARGETED THERAPY;

EID: 84898909262     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12481     Document Type: Article

References (45)

1. Shiraha H, Yamamoto K, Namba M. Human hepatocyte carcinogenesis (review). Int. J. Oncol. 2013; 42: 1133-1138.
2. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch. Intern. Med. 2000; 160: 3227-3230.
3. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J. Gastroenterol. 2008; 14: 4300-4308.
4. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-1832.
5. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-S112.
6. Bugianesi E, Leone N, Vanni E etal. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-140.
7. Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin. Liver Dis. 2007; 11: 1-16.
8. Rosmorduc O, Fartoux L. HCC and NASH: how strong is the clinical demonstration? Clin. Res. Hepatol. Gastroenterol. 2012; 36: 202-208.
9. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-669.
10. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000; 32: 689-692.
11. Cabibbo G, Maida M, Genco C, Antonucci M, Cammà C. Causes of and prevention strategies for hepatocellular carcinoma. Semin. Oncol. 2012; 39: 374-383.
12. Bellentani S, Dalle Grave R, Suppini A, Marchesini G. Fatty Liver Italian Network. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology 2008; 47: 746-754.
13. Luethy JD, Holbrook NJ. Activation of the gadd153 promoter by genotoxic agents: a rapid and specific response to DNA damage. Cancer Res. 1992; 52: 5-10.
14. Cazanave SC, Elmi NA, Akazawa Y, Bronk AF, Mott JL, Gores HJ. CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2010; 299: G236-243.
15. Pfaffenbach KT, Gentile CL, Nivala AM, Wang D, Wei Y, Pagliassotti MJ. Linking endoplasmic reticulum stress to cell death in hepatocytes: roles of C/EBP homologous protein and chemical chaperones in palmitate-mediated cell death. Am. J. Physiol. Endocrinol. Metab. 2010; 298: E1027-1035.
16. Puri P, Mirshahi F, Cheung O etal. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology 2008; 134: 568-576.
17. Crozat A, Aman P, Mandahl N, Ron D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 1993; 363: 640-644.
18. Forus A, Flørenes VA, Maelandsmo GM, Fodstad O, Myklebost O. The protooncogene CHOP/GADD153, involved in growth arrest and DNA damage response, is amplified in a subset of human sarcomas. Cancer Genet. Cytogenet. 1994; 78: 165-171.
19. Chu HH, Bae JS, Kim KM etal. Expression of CHOP in squamous tumor of the uterine cervix. Korean. J. Pathol. 2012; 46: 463-469.
20. Oyadomari S, Takeda K, Takiguchi M etal. Nitric oxide-induced apoptosis in pancreatic β cells is mediated by the endoplasmic reticulum stress pathway. Proc. Natl. Acad. Sci. U.S.A. 2001; 98: 10845-10850.
21. Rahman SM, Schroeder-Gloeckler JM, Janssen RC etal. CCAAT/enhancing binding protein beta deletion in mice attenuates inflammation, endoplasmic reticulum stress, and lipid accumulation in diet-induced nonalcoholic steatohepatitis. Hepatology 2007; 45: 1108-1117.
22. Nagata H, Hatano E, Tada M etal. Inhibition of c-Jun NH2-terminal kinase switches Smad3 signaling from oncogenesis to tumor-suppression in rat hepatocellular carcinoma. Hepatology 2009; 49: 1944-1953.
23. López-De León A, Rojkind M. A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J. Histochem. Cytochem. 1985; 33: 737-743.
24. Tamaki N, Hatano E, Taura K etal. CHOP deficiency attenuates cholestasis-induced liver fibrosis by reduction of hepatocyte injury. Am. J. Physiol. Gastrointest. Liver Physiol. 2008; 294: G498-505.
25. Kleiner DE, Brunt EM, Van Natta M etal. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
26. Yamanaka K, Hatano E, Narita M etal. Olprinone attenuates excessive shear stress through up-regulation of endothelial nitric oxide synthase in a rat excessive hepatectomy model. Liver Transpl. 2011; 17: 60-69.
27. Tomita K, Tamiya G, Ando S etal. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 2006; 55: 415-424.
28. Hashimoto E, Yatsuji S, Tobari M etal. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J. Gastroenterol. 2009; 19: 89-95.
29. Takizawa D, Kakizaki S, Horiguchi N, Yamazaki Y, Tojima H, Mori M. Constitutive active/androstane receptor promotes hepatocarcinogenesis in a mouse model of non-alcoholic steatohepatitis. Carcinogenesis 2011; 32: 576-583.
30. Marchesini G, Bugianesi E, Forlani G etal. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923.
31. Sun B, Karin M. Obesity, inflammation, and liver cancer. J. Hepatol. 2012; 56: 704-713.
32. Neuschwander-Tetri BA, Ford DA, Acharya S etal. Dietary trans-fatty acid induced NASH is normalized following loss of trans-fatty acids from hepatic lipid pools. Lipids 2012; 47: 941-951.
33. Park EJ, Lee JH, Yu GY etal. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140: 197-208.
34. Schattenberg JM, Schuchmann M. Diabetes and apoptosis: liver. Apoptosis 2009; 14: 1459-1471.
35. Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin. Liver Dis. 2008; 28: 360-369.
36. Trauner M, Arrese M, Wagner M. Fatty liver and lipotoxicity. Biochim. Biophys. Acta 2010; 1801: 299-310.
37. Fu S, Watkins SM, Hotamisligil GS. The role of endoplasmic reticulum in hepatic lipid homeostasis and stress signaling. Cell Metab. 2012; 15: 623-634.
38. Oyadomari S, Mori M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ. 2004; 11: 381-389.
39. McCullough KD, Martindale JL, Klotz LO, Aw TY, Holbrook NJ. Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. Mol. Cell. Biol. 2001; 21: 1249-1259.
40. Matsumoto M, Minami M, Takeda K, Sakao K, Akira S. Ectopic expression of CHOP (Gadd153) induces apoptosis in M1 myeloblastic leukemia cells. FEBS Lett. 1996; 395: 143-147.
41. Strasser A. The role of BH3-only proteins in the immune system. Nat. Rev. Immunol. 2005; 5: 189-200.
42. Schulte-Hermann R, Bursch W, Grasl-Kraupp B, Müllauer L, Ruttkay-Nedecky B. Apoptosis and multistage carcinogenesis in rat liver. Mutat. Res. 1995; 333: 81-87.
43. Fausto N. Mouse liver tumorigenesis: models, mechanisms, and relevance to human disease. Semin. Liver Dis. 1999; 19: 243-252.
44. Canbay A, Feldstein AE, Higuchi H etal. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 2003; 38: 1188-1198.
45. Fausto N, Campbell JS, Riehle KJ. Liver regeneration. Hepatology 2006; 43: S45-53.